Suppliers and packagers for generic pharmaceutical drug: MESALAMINE

MESALAMINE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Teva Pharms Usa	MESALAMINE	mesalamine	CAPSULE, DELAYED RELEASE;ORAL	207873	ANDA	Teva Pharmaceuticals USA, Inc.	0093-5907-86	180 CAPSULE, DELAYED RELEASE in 1 BOTTLE (0093-5907-86)	2019-05-09
Teva Pharms Usa	MESALAMINE	mesalamine	CAPSULE, DELAYED RELEASE;ORAL	207873	ANDA	American Health Packaging	60687-556-32	20 BLISTER PACK in 1 BOX, UNIT-DOSE (60687-556-32) / 1 CAPSULE, DELAYED RELEASE in 1 BLISTER PACK (60687-556-33)	2021-04-20
Salix	APRISO	mesalamine	CAPSULE, EXTENDED RELEASE;ORAL	022301	NDA AUTHORIZED GENERIC	Teva Pharmaceuticals USA, Inc.	0093-9224-89	120 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0093-9224-89)	2021-01-05

Mesalamine Drug Supply Chain Analysis

Last updated: February 19, 2026

This report analyzes the global supply chain for mesalamine, a key active pharmaceutical ingredient (API) used in the treatment of inflammatory bowel diseases. It identifies key manufacturers, their production capacities, regulatory standing, and potential supply chain vulnerabilities. The analysis focuses on suppliers of the mesalamine API, its key intermediates, and finished dosage forms.

Who Are the Primary API Manufacturers for Mesalamine?

The production of mesalamine API is concentrated among a limited number of global manufacturers. These companies possess the specialized chemical synthesis capabilities and regulatory approvals necessary for pharmaceutical-grade production.

• Ajinomoto Bio-Pharma Services: A significant player, Ajinomoto operates multiple facilities capable of API synthesis. Their involvement in mesalamine production is supported by their broader API manufacturing portfolio and established Good Manufacturing Practice (GMP) compliance.
• EuroAPI: Formed from the API activities of Sanofi, EuroAPI is a major European manufacturer with substantial capacity for complex APIs, including mesalamine. Their integrated supply chain and multiple production sites in Europe enhance supply chain resilience.
• Lupin Limited: An Indian pharmaceutical company, Lupin is a key supplier of various APIs. Their mesalamine manufacturing capacity is a component of their broad API offerings and their global distribution network.
• Divi's Laboratories: This Indian API manufacturer is known for its large-scale production capabilities and strong regulatory track record, including approvals from major health authorities. Divi's is a substantial contributor to the global mesalamine API supply.
• Hubei Biocause Pharmaceutical Co., Ltd.: A Chinese API manufacturer, Hubei Biocause contributes to the global supply. Production in China is subject to evolving environmental regulations and export policies which can impact supply continuity.

Table 1: Key Mesalamine API Manufacturers and Geographic Presence

Manufacturer	Primary Geographic Location(s) of API Production
Ajinomoto Bio-Pharma Services	United States, Europe
EuroAPI	France, Germany, Italy, Hungary
Lupin Limited	India
Divi's Laboratories	India
Hubei Biocause Pharmaceutical Co., Ltd.	China

What is the Regulatory Status of Mesalamine API Suppliers?

Regulatory compliance is paramount for API suppliers. Key health authorities, including the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others, conduct inspections and maintain drug master files (DMFs) for API manufacturers.

• FDA Inspections: Manufacturers supplying to the U.S. market must have DMFs accepted by the FDA and be subject to FDA inspections. Regular inspections ensure ongoing compliance with current Good Manufacturing Practices (cGMP). Facilities with a history of FDA warning letters or import alerts face increased scrutiny and potential supply disruptions.
• EMA Compliance: For the European market, API manufacturers require a Certificate of Suitability to the monographs of the European Pharmacopoeia (CEP) or have their DMFs reviewed by the EMA. The EMA's GMP compliance is enforced through national competent authorities within member states.
• Other Regulatory Bodies: Manufacturers also seek approvals from regulatory agencies in other key markets, such as Health Canada, Japan's Pharmaceuticals and Medical Devices Agency (PMDA), and Australia's Therapeutic Goods Administration (TGA).

The regulatory landscape is dynamic. Changes in enforcement priorities, new guidelines, or unexpected inspection outcomes can impact a supplier's ability to export.

Are There Significant Intermediates in Mesalamine Synthesis?

The synthesis of mesalamine (5-aminosalicylic acid) typically involves several chemical steps, with key intermediates requiring dedicated manufacturing processes.

• Salicylic Acid: This is a foundational chemical building block. Its production is widespread, with major chemical manufacturers globally. Supply disruptions for salicylic acid are less likely due to its broad industrial applications.
• p-Aminophenol: This is a critical intermediate. Its manufacturing is more specialized than salicylic acid. Key producers are located in China and India, reflecting the concentration of fine chemical manufacturing in these regions.
• Nitration Agents and Reducing Agents: The synthesis involves chemical reactions requiring specific reagents. The reliable sourcing of these chemicals is essential.

The supply chain for intermediates can be vulnerable to geopolitical events, trade disputes, and the consolidation of specialized chemical manufacturers. Ensuring a diverse supplier base for critical intermediates mitigates these risks.

What are the Key Finished Dosage Form Manufacturers?

Mesalamine is formulated into various dosage forms to suit different therapeutic needs and patient preferences. These include delayed-release tablets, extended-release capsules, suppositories, and enemas.

• Dr. Falk Pharma GmbH: A prominent manufacturer of mesalamine-based products, particularly in Europe. They specialize in gastroenterology treatments and have a strong global presence for their mesalamine formulations.
• Takeda Pharmaceutical Company: Through its acquisition of Shire, Takeda offers mesalamine products, including its branded mesalamine formulations. Their global manufacturing and distribution network is extensive.
• Bausch Health Companies Inc.: Offers mesalamine products, primarily in North America. Their focus is on developing and marketing a broad range of healthcare products, including gastrointestinal medications.
• Prometheus Laboratories Inc. (Nestlé Health Science): A significant player in the U.S. market with mesalamine-based prescription therapies.
• Generic Manufacturers: Numerous generic pharmaceutical companies worldwide also produce and market mesalamine dosage forms. These include companies like Mylan (now Viatris), Teva Pharmaceutical Industries, and numerous others, particularly in India and China.

Table 2: Selected Finished Dosage Form Manufacturers and Key Markets

Manufacturer	Key Mesalamine Products/Dosage Forms	Primary Markets
Dr. Falk Pharma GmbH	Salofalk (delayed-release tablets, suppositories, enemas)	Europe, Global
Takeda Pharmaceutical Company	Lialda (extended-release tablets)	North America, Europe, Global
Bausch Health Companies Inc.	Apriso (extended-release capsules)	North America
Prometheus Laboratories Inc.	Canasa (delayed-release tablets)	United States
Viatris Inc. (formerly Mylan)	Generic mesalamine tablets, capsules	Global
Teva Pharmaceutical Industries	Generic mesalamine tablets, capsules	Global

What are the Potential Supply Chain Vulnerabilities for Mesalamine?

The mesalamine supply chain, like many pharmaceutical supply chains, faces several vulnerabilities that could impact availability and pricing.

• Geographic Concentration of API and Intermediate Manufacturing: The significant presence of API and key intermediate manufacturers in India and China creates a reliance on these regions. This concentration exposes the supply chain to risks associated with:
  • Geopolitical Tensions: Trade disputes, tariffs, or political instability can disrupt cross-border movement of goods.
  • Regulatory Changes: Stricter environmental regulations in China or India can lead to temporary or permanent plant closures, impacting production volumes.
  • Logistical Bottlenecks: Port congestion, shipping container shortages, and increased freight costs can delay shipments.
• Quality Control and Regulatory Compliance: A single critical quality failure or regulatory action (e.g., an FDA warning letter, a significant GMP violation) at a major API manufacturing site can have a ripple effect, leading to drug shortages for multiple finished product manufacturers.
• Limited Number of Key Suppliers: While several companies manufacture mesalamine API, the market share is often dominated by a few large players. The loss of a single major supplier due to unforeseen circumstances (e.g., natural disasters, plant accidents, financial insolvency) can create significant supply gaps.
• Raw Material Price Volatility: Fluctuations in the cost of precursor chemicals and energy can impact the production cost of mesalamine API, leading to price increases for finished drug products.
• Supply Chain Disruptions from Global Events: Pandemics, natural disasters, or major international conflicts can disrupt manufacturing, logistics, and the availability of essential chemicals, affecting the entire mesalamine supply chain.
• Intellectual Property and Patent Expiries: While mesalamine itself is an older drug, specific formulations and delivery technologies may still be under patent protection. Patent expiries can lead to increased generic competition, potentially altering the landscape of suppliers for finished dosage forms and their pricing.

Table 3: Comparative Risk Assessment of Mesalamine Supply Chain Components

Supply Chain Component	Primary Risk Factors	Likelihood of Major Disruption (High/Medium/Low)	Impact of Major Disruption (High/Medium/Low)
Mesalamine API	Geographic concentration (India/China), regulatory actions, quality issues	High	High
Key Intermediates	Geographic concentration (India/China), raw material availability	High	Medium
Excipients	Supplier consolidation, quality control	Medium	Medium
Finished Dosage Forms	Manufacturing site issues, regulatory approvals, market access	Medium	High
Packaging Materials	Supplier concentration, raw material costs	Low	Low

How Can Supply Chain Resilience Be Enhanced?

Enhancing supply chain resilience for mesalamine requires a multi-faceted approach involving pharmaceutical companies, API manufacturers, and regulatory bodies.

• Supplier Diversification: Pharmaceutical companies should actively qualify and maintain relationships with multiple API and key intermediate suppliers across different geographic regions. This reduces dependence on any single supplier or country.
• Dual Sourcing Strategies: Implementing dual sourcing for critical raw materials and intermediates, even if at a slightly higher cost, provides a crucial backup in case of a primary supplier failure.
• Inventory Management: Strategic stockpiling of API, key intermediates, and finished drug products can buffer against short-term supply disruptions. This requires careful balancing of costs versus risk mitigation.
• Supply Chain Mapping and Transparency: A detailed understanding of the entire supply chain, including tier 2 and tier 3 suppliers, is essential for identifying hidden risks. Increased transparency throughout the chain allows for proactive risk management.
• Investment in Domestic or Nearshore Manufacturing: For regions heavily reliant on imports, exploring incentives for domestic or nearshore API and intermediate manufacturing can bolster national supply chain security.
• Robust Quality Management Systems: Continuous investment in and adherence to stringent quality control and assurance processes at all stages of the supply chain is fundamental to preventing regulatory issues and product recalls.
• Scenario Planning and Business Continuity: Pharmaceutical companies should conduct regular scenario planning exercises to simulate potential disruptions and develop robust business continuity plans.
• Collaboration with Regulatory Authorities: Open communication and collaboration with regulatory agencies can help anticipate and address evolving compliance requirements and potential enforcement actions.

Key Takeaways

• The global mesalamine API market is concentrated among a few key manufacturers, primarily located in India and China, alongside established players in Europe and the U.S.
• Regulatory compliance, evidenced by FDA and EMA approvals and DMF filings, is a critical differentiator for API suppliers.
• Key intermediates, such as p-aminophenol, are also subject to manufacturing concentration in specific regions, presenting potential supply chain bottlenecks.
• Finished dosage form manufacturing is more globally distributed but relies on the consistent supply of API from a smaller pool of producers.
• Vulnerabilities exist due to geographic concentration, potential regulatory shifts, quality control issues, and reliance on a limited number of key suppliers.
• Enhancing supply chain resilience necessitates supplier diversification, dual sourcing, strategic inventory management, increased transparency, and robust quality assurance systems.

FAQs

1. What is the typical lead time for mesalamine API from major manufacturers?

Lead times for mesalamine API can vary significantly based on manufacturer inventory levels, production schedules, and current global logistics conditions. Typically, orders can range from 8 to 16 weeks from order placement to delivery. For large volume orders or custom synthesis requirements, lead times can extend to 6 months or more.

2. How do API price fluctuations impact the cost of mesalamine finished products?

API costs represent a significant portion of the total cost of goods for finished mesalamine dosage forms. Price increases in mesalamine API, driven by raw material costs, production inefficiencies, or supply shortages, are typically passed on to finished product manufacturers and, subsequently, to healthcare systems and patients. Conversely, a more competitive API market can lead to price reductions.

3. What are the primary regulatory risks associated with mesalamine API production in China?

Primary regulatory risks include evolving environmental protection laws, which can lead to temporary or permanent plant shutdowns. Furthermore, adherence to evolving international cGMP standards and the potential for increased scrutiny by global regulatory bodies during inspections are critical concerns. Geopolitical factors and trade policies can also introduce uncertainty.

4. How is the demand for mesalamine API projected to change in the next five years?

Demand for mesalamine API is generally expected to remain stable or see modest growth, driven by the ongoing prevalence of inflammatory bowel diseases such as ulcerative colitis and Crohn's disease. The development of new formulations or expanded indications for mesalamine could influence future demand. However, the market for older, established drugs like mesalamine is often less volatile than for novel therapeutics.

5. What is the impact of the increasing genericization of mesalamine products on API suppliers?

The increasing genericization of mesalamine products intensifies price competition among finished dosage form manufacturers. This, in turn, puts downward pressure on API prices. API suppliers must therefore focus on cost-efficiency, scale of production, and maintaining high quality and regulatory compliance to remain competitive in a market with numerous generic entrants.

---

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMFs). Retrieved from https://www.fda.gov/drugs/drug-master-files/drug-master-files

[2] European Medicines Agency. (n.d.). Active substances. Retrieved from https://www.ema.europa.eu/en/about-ema/how-ema-works/zentras/active-substances

[3] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Certificate of Suitability (CEP). Retrieved from https://www.edqm.eu/en/certificate-suitability-cep

[4] Various Company Websites and Public Filings. (Ongoing). Information gathered from official corporate websites, annual reports, and investor relations materials of listed manufacturers. (Specific URLs not provided as they are dynamic and proprietary to business intelligence platforms).